Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
The company said prula-cel was well tolerated, with no CRS above grade 2 and no IEC-HS or ICANS. It plans pivotal lupus nephritis trial start-up activities in Q4 2026 and expects a further data update in mid-2027.
Adicet Bio said prula-cel study data were positive for safety and efficacy in patients with systemic lupus erythematosus, with or without lupus nephritis.
Adicet Bio reported positive safety and efficacy from a Phase 1 study of prula-cel in SLE with or without lupus nephritis, and plans to initiate start-up activities for a single-arm pivotal LN study in Q4 2026 with complete renal response at 12 months as the primary endpoint.Material DetailsContext…